Save up -80% on Crizotinib
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Xalkori
|$17,062.91||60 capsules/250 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Crizotinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Crizotinib every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Crizotinib volume of distribution
Mean volume of distribution (Vss) is 1772 L following intravenous administration of a 50 mg dose. This high volume of distribution suggest extensive distribution into tissue from plasma.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Crizotinib
Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular’s Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Crizotinib mechanism of action
Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d’Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.
Dosage forms of Crizotinib
(R)-Crizotinib C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Pfizer Laboratories Div Pfizer Inc
Humans and other mammals
Indication of Crizotinib
Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Toxicity of Crizotinib
Pulmonary toxicity from crizotinib is a rare, but potentially life-threatening, adverse reaction. This rare toxicity has been seen with other small-molecule tyrosine kinase inhibitors, including gefitinib and erlotinib. In profile 1001 and 1005, severe pneumonitis was seen in 1.6% (4 of 255) of patients16. Typically, the event happened within 2 months after initiation of treatment. Cases of fatal crizotinib-induced pneumonitis have occurred 27.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Crizotinib on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.